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Abstract 
Background: Sepsis is a common condition that has a high mortality and morbidity that need prompt diagnosis 
and treatment. Biomarkers like Soluble CD14 subtype (sCD14-ST, presepsin) may be useful in identifying patients 
with sepsis and its diagnostic superiority has been confirmed by several preliminary studies. The aim of this study was 
systematically and quantitatively to evaluate the value of presepsin for the diagnosis of sepsis through the method of 
meta-analysis.
Methods: Four major databases, including MEDLINE, EMBASE, ISI Web of Knowledge, and the Cochrane Library were 
systematically searched from inception to March 2015. Two investigators conducted the processes of literature search, 
study selection, data extraction, and quality evaluation independently. And the original data were extracted from all 
eligible individual studies to construct two-by-two tables.
Results: A total of eight studies comprising 1757 patients were included in this meta-analysis. The pooled sensitivity, 
specificity, and diagnostic odds ratio were 0.77 (95 % confidence interval [CI]: 0.75–0.80), 0.73 (95 % CI 0.69–0.77), and 
14.25 (95 % CI 8.66–23.42), respectively. The summary receiver operating characteristic curve (SROC) area under the 
curve (AUC) was 0.8598. The subgroup analysis based on excluding the outliers showed that the pooled sensitivity 
and specificity were 0.85 (95 % CI 0.81–0.89) and 0.65 (95 % CI 0.59–0.70), respectively. The AUC was 0.8213 with no 
significant heterogeneity.
Conclusions: Presepsin has moderate diagnostic capacity for the detection of sepsis. Further research of presepsin 
is needed before widespread use in emergency department. And presepsin in combination with other laboratory 
biomarkers in diagnosing sepsis may be the focus of future studies.
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Background
Sepsis is a condition in which the immune system over-
reacts to infection, releasing inflammatory mediators 
into the peripheral blood and triggering widespread 
inflammation. Early detection and timely treatment of 
the above pathologic processes may be able to prevent 
the occurrence of multiple organ dysfunction (MODS) 
induced by severe sepsis and septic shock. Sepsis occurs 
in 1–2 % of all hospitalizations, and it is the leading cause 
of mortality in critically ill patients [1, 2]. Despite modern 
antibiotic therapy in combined with cardiovascular and 
respiratory support, mortality rates still remain between 
30 and 60 % [3–5]. Therefore, early diagnosis and treat-
ment are hot topic among intensivists [5].
However, rapid and accurate diagnosis of sepsis is 
often difficult in routine clinical practice because the 
clinical manifestations of this condition can overlap 
with many non-infectious causes of systemic inflam-
mation, such as pancreatitis, ischemia, multiple 
trauma, and hemorrhagic shock, which are collectively 
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termed a systemic inflammatory response syndrome 
(SIRS) [6]. Microbiological culture is considered as the 
reference standard in diagnosing infectious condition, 
whereas it usually needs several days to obtain the 
results [7].
Presepsin, also named soluble cluster-of-differentia-
tion 14 subtype (sCD14-ST), is a 13 kDa protein that is 
a truncated N-terminal fragment of CD14 [8]. CD14 is 
a high-affinity receptor for complexes of lipopolysac-
charide (LPS) and LPS-binding proteins (LPB), which 
is a multifunction cell surface glycoprotein expressed 
on the surface of various cells including monocytes, 
macrophages, neutrophils, and B cells [9, 10]. By shed-
ding of CD14 from the cell membrane and releasing 
into circulation during infection status, the LPS–LPB–
CD14 complex yields soluble CD14. Then, sCD14 is 
activated by plasma proteases during the circulating 
process, and thus generates a 13  kDa protein named 
sCD14-ST or presepsin. Presepsin increases signifi-
cantly in the blood of sepsis patients, and it has been 
studied as a marker to differentiate sepsis from other 
non-infectious causes of SIRS [8]. The results of sev-
eral early studies were encouraging, and it has been 
reported that the diagnostic value of presepsin was 
superior to procalcitonin (PCT) and C-reactive pro-
tein (CRP) [11, 12]. However, few studies produced 
disappointing results [13, 14]. Meanwhile, many stud-
ies included patients who did not have SIRS. This may 
add further uncertainty in assessing the diagnostic 
accuracy of presepsin. Thus, the aim of our study was 
to systematically explore the diagnostic value of prese-
psin in patients with sepsis.
Methods
The present meta-analysis was conducted and reported 
according to the Preferred Reporting Items for System-
atic Reviews and Meta-analyses Statement (PRISMA).
Data sources
MEDLINE, Excerpta Medica database (EMBASE), ISI 
Web of Knowledge, and Cochrane Library databases 
were searched from the inception to March 2015. The 
following keywords or medical subject headings(MeSH) 
were used: “presepsin” or “sCD14-ST” or “soluble CD-14 
subtype” or “soluble cluster of differentiation 14 sub-
type” and “sepsis” or “SIRS” or “systemic inflammatory 
response syndrome” or “infection.” We also searched the 
abstracts that were presented at the annual meetings of 
the American College of Emergency Physicians, the Soci-
ety of Critical Care Medicine, and the Society for Aca-
demic Emergency Medicine. The reference lists of eligible 
articles and related reviews were also screened to identify 
further studies.
Eligibility criteria
Two reviewers (ZJZ) and (LBJ) independently evaluated 
the studies for their eligibility to be included. In cases of 
disagreement, a consensus was reached by discussion or 
by consultation to a third reviewer (LGY). Studies were 
considered eligible if the following criteria were met: pro-
viding the presepsin concentrations of sepsis patients and 
non-sepsis patients; having sufficient data to construct the 
2 × 2 contingency table; having a well-defined reference 
standard about diagnosing sepsis(defined by the Ameri-
can College of Chest Physicians/Society of Critical Care 
Medicine Consensus Conference, ACCP/SCCM) [15].
Reviews, correspondence, editorials, and conference 
abstracts were excluded. Studies with the same authors 
were cautiously investigated. Studies were also excluded 
if they were limited to restrictive subgroups, such as 
some special types of sepsis like burn sepsis. However, 
their reference lists were screened to identify further 
studies for inclusion.
Data extraction
The following items were extracted using a specific sheet 
which was constructed in advance: authors and year of 
study, the country, study design, patient setting, number and 
characteristics of patients, presepsin measuring instrument, 
cut-off point, prevalence of sepsis, diagnostic sensitivity and 
specificity, inclusion criteria, and reference standard. Two 
reviewers independently extracted the data from each study. 
Disagreements were resolved by consensus.
Quality assessment
The methodological quality of all individual study was 
assessed using the QUADAS-2 tool [16], which was rec-
ommended by the Cochrane handbook for diagnostic 
test accuracy reviews. The QUADAS-2 tool comprises 
four domains: patient selection, index test, reference 
standard, and flow and timing. Each domain is assessed 
in terms of risk of bias, and the first three domains are 
also assessed in terms of concerns regarding applicability. 
Signaling questions are included to help judge the risk of 
bias of each study. The assessment was performed inde-
pendently by two reviewers (ZJZ, LBJ). Disagreements 
were resolved by consensus.
Statistical analysis
True positive (TP), false positive (FP), false negative (FN), 
and true negative (TN) were obtained from each study. 
Sensitivity and specificity with its 95 % confidence were 
calculated from the 2  ×  2 contingency table of each 
study. We added 1/2 to all cells of the studies with zero. 
Meanwhile, the meta-analysis was performed by calculat-
ing the pooled sensitivity, specificity, positive likelihood 
ratio (LR), negative LR, and diagnostic odds ratios (OR). 
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Pooled results were constructed by using either the fixed-
effect model when significant heterogeneity was absent 
or the random-effect model when significant heterogene-
ity was present [17].
Heterogeneity of the included studies was explored 
using the Cochrane Q test. Inconsistency (I2) expresses 
the variability attributable to heterogeneity across the 
studies in the form of a percentage. The spearman coeffi-
cient between the logit of sensitivity and logit of 1-speci-
ficity was performed to test threshold effect and a strong 
positive correlation indicates threshold effect [18]. There 
were several other factors that might contribute to the 
heterogeneity, including patient setting, characteristics of 
patients, presepsin measuring instrument, inclusion cri-
teria, and reference standard [19]. I2 > 50 % or P < 0.05 
suggested the presence of significant heterogeneity 
among included studies [20]. If substantial heterogene-
ity was found, the meta-regression techniques would be 
used to explore the reasons for the heterogeneity. Meta-
regression was made using a generalization of Litten-
berg and Moses Linear model. The model was weighted 
by inverse of the variance or study size [18, 19]. In addi-
tion, subgroup analyses were performed according to the 
result of meta-regression.
Finally, if the studies were reasonably homogeneous, 
an AUC was calculated. The closer that the value of the 
area under the curve is to 1, the better validated the diag-
nostic test is. What’s more, we used a Q* point from the 
SROC curve to obtain the maximum joint sensitivity 
and specificity. The Q* point is the intersection between 
a symmetrical SROC curve and the antidiagonal line, at 
which sensitivity equals specificity. Comparing to other 
parameters, Q* point is a single-number summarizing of 
the test performance and has the advantage of being less 
affected by heterogeneity [18, 21].
Publication bias was tested by Deeks’ asymmetry test 
and a funnel plot. The slope coefficient with P < 0.05 indi-
cated the presence of publication bias.
All analyses including the pooling of sensitivity, speci-
ficity, positive LR, negative LR, diagnostic OR, SROC 
curve, and meta-regression were conducted using free-
ware Meta-Disc, version 1.4 (Ramon Y Cajal Hospital, 
Madrid, Spain) [22]. Study quality was performed using 
Review Manager 5.3 (Oxford, UK: The Cochrane Col-
laboration). Publication bias was performed using Stata 
version 12.0 (Stata Corporation, College Station, Tex). 




The flow diagram of study selection is shown in Fig.  1. 
A total of 135 records were retrieved by searching the 
databases of MEDLINE, EMBASE, ISI Web of Knowl-
edge, and Cochrane Library databases. After removing 
the 14 duplicates, the titles and abstracts of the remain-
ing 121 records were screened. Then, 61 apparently irrel-
evant studies were excluded, and 60 potentially relevant 
articles were identified for further review.
After full-text review, 52 articles were excluded: 31 
were Conference abstracts, four were review articles 
[23–26], two were correspondence letters [8, 27], one was 
editorial [28], three studied on neonates and had differ-
ent reference standards [29–31], three did not have suf-
ficient data to reconstruct the 2 × 2 contingency table [9, 
32, 33], one had no SIRS patients in control group [34], 
one had health people in control group and it had differ-
ent inclusion and exclusion criteria compared to our cri-
teria [35], three had too narrow a spectrum of patients 
[36–38], one was about other infectious disease [39], and 
two studies were designed of self pre- and post-control 
observation [40, 41].
Finally, eight studies fulfilled the inclusion criteria and 
were eligible for our meta-analysis [7, 12, 13, 42–46]. The 
characteristics of all eight studies included in our analy-
sis are shown in Table  1. A total of 1757 patients were 
included in our meta-analysis, of which, 1240 were emer-
gency department visits. The prevalence of sepsis ranged 
from 16.37 to 85.11  %. All the studies used a compact 
automated immune analyzer PATHFAST (Japan or Ger-
many), which is based on a chemiluminescent enzyme 
immunoassay, to determine the plasma presepsin con-
centrations. The test threshold of presepsin of diagnosing 
sepsis ranged from 317 to 729 pg/ml.
Quality of studies
Details of the methodological assessment are shown 
in Fig. 2. We evaluated the quality of the eight included 
studies using the QUADAS-2 tool. According to the 
results of methodological assessment, all included stud-
ies possessed acceptable quality. The ACCP/SCCM 
guideline was used to diagnose sepsis in all studies, and 
the same index test criterion was applied to each patient. 
Meanwhile, all of them used a prospective study design. 
However, all the studies did not pre-specify a thresh-
old except one [46]. There is no evidence that the refer-
ence standard results of the studies interpreted without 
knowledge of the results of the index test except one [44].
Heterogeneity exploration and data synthesis
In the exploration of heterogeneity, the Spearman corre-
lation coefficient between the logit of sensitivity and logit 
of 1-specificity was 0.190 (P =  0.651) with the slope of 
the regression line near zero, suggesting that there was 
no significant threshold effect present among the eight 
studies.
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The SROC of presepsin is shown in Fig.  3, generating 
an AUC of 0.8598 (Q* = 0.7906). A random effects model 
was used to calculate the pooled mean difference and the 
95  % confidence interval. The pooled diagnostic odds 
ratio of the eight studies was 14.25 (95 % CI 8.66–23.42). 
The pooled sensitivity and pooled specificity were 0.77 
(95 % CI 0.75–0.80) and 0.73 (95 % CI 0.69–0.77), respec-
tively (Fig. 4). The pooled positive LR and pooled negative 
LR were 3.11 (95 % CI 2.16–4.50) and 0.22 (95 % CI 0.16–
0.32), respectively (Fig. 5). However, substantial degree of 
heterogeneity was observed in the summary estimates.
Meta‑regression
Since obvious heterogeneity was observed, the 
meta-regression technique was used to explore the 
heterogeneity other than threshold effect. The result is 
shown in Table 2. A substantial heterogeneity caused by 
the measuring instrument was found, and the subgroup 
analysis was performed by restricting studies to a similar 
measuring instrument (PATHFAST, Mitsubishi Chemical 
Medience Corporation, Japan).
The analysis included four studies [7, 12, 42, 43],the 
SROC is shown in Fig.  6, and the AUC was 0.8946 
(Q*  =  0.8255). The pooled sensitivity (random-effect 
model) and pooled specificity (fixed-effect model) were 
0.75 (95  % CI 0.72–0.78) and 0.84 (95  % CI 0.79–0.88), 
respectively. The pooled positive LR (fixed-effect model) 
and pooled negative LR (random-effect model) were 4.82 
(95 % CI 3.69–6.30) and 0.18 (95 % CI 0.09–0.35), respec-
tively. The pooled diagnostic odds ratio was 18.57 (95 % 
Fig. 1 Identification, inclusion, and exclusion of the studies
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CI 12.98–26.56). The result is shown in Table 3. However, 
there was still heterogeneity in pooled sensitivity and 
pooled negative LR (I2 = 91.4 % & I2 = 86.8 %).
Subgroup analysis
By observing the forest plots, the studies by Liu et al. and 
Endo et  al. were found to be outliers and may account 
for most of the heterogeneity. After excluding these two 
studies, the heterogeneity diminished significantly. Sub-
group analysis based on the rest of studies was performed 
with a fixed effects model, and the results are shown in 
Table  4. The pooled sensitivity, specificity, positive LR, 
negative LR, and diagnostic OR were 0.85 (95 % CI 0.81–
0.89), 0.65 (95 % CI 0.59–0.70), 2.46 (95 % CI 2.03–2.98), 
0.25 (95 % CI 0.19–0.33), and 9.47 (95 % CI 6.38–14.05), 
respectively. The SROC of these six studies are shown in 
Fig. 7 and the AUC was 0.8213 (Q* = 0.7547).
Publication bias exploration
We used the Egger’s regression model to detect the 
publication bias, and the result is shown in Fig.  8. The 
Deeks’ funnel plot did not show significant asymmetry 
(P = 0.755), indicating that there was no significant pub-
lication bias in this meta-analysis.
Fig. 2 Risk of bias and applicability concerns
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Discussion
The present systematic review and meta-analysis 
explored the accuracy of presepsin for the diagnosis of 
sepsis from SIRS patients. And the results showed that 
the biomarker presepsin had the acceptable pooled sen-
sitivity (0.77) and pooled specificity (0.73). Accordingly, 
the AUC was 0.8598, indicating that the presepsin had a 
moderate diagnostic efficiency.
Sepsis causes millions of deaths globally each year 
and occurs in 1–2 % of all hospitalizations in the United 
States, affecting at least 750,000 persons and costing 
$17 billion per year to treat [1, 2]. As the high morbid-
ity and mortality of sepsis, early diagnosis and treatment 
are essential to improve the prognosis of these patients 
[5]. However, due to the existence of other non-infectious 
causes of systemic inflammation (SIRS), it is critical to 
find a reliable biomarker to differentiate sepsis from SIRS 
at the early stage.
Various biological markers such as PCT, CRP, interleu-
kins, and myeloid cells expressing triggering receptor-1 
(TREM-1) have been reported as biomarkers in diagnosis 
with sepsis [47–49]. However, their clinical values are still 
controversial and uncertain except PCT. Meanwhile, the 
gold standard microbiological culture, which is used to 
distinguish infectious diseases from non-infectious con-
ditions, lacks sensitivity and specificity, and there is often 
a substantial time delay [7].
As a new and promising biomarker, presepsin was 
first found in 2004 and has been revealed to be with 
superior diagnostic capacity when compared with 
other conventional diagnostic markers [11, 12]. Presep-
sin is a 13-kDa protein that is a fragment of CD14 with 
Fig. 3 The SROC of presepsin for diagnosis sepsis
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truncated N-terminal, the receptor for LPS/LBP com-
plexes. It was identified as a protein whose levels increase 
specifically in the blood of sepsis patients. Vodnik et al. 
found that presepsin values were significantly higher 
in patients with sepsis (1508.3 ± 866.6 pg/mL) than the 
SIRS (430.0  ±  141.33  pg/mL) group (P  <  0.0001) [38]. 
However, the results of few studies showed considerable 
differences, such as in the sensitivity range (0.71–0.93) 
and in the specificity range (0.60–0.86). Therefore, it is 
important for a meta-analysis to evaluate the value of a 
single laboratory test to identify patients at increased risk 
of sepsis from independent studies.
The meta-analysis presented above showed no 
threshold effect and significant publication bias. 
In addition, meta-regression was performed and a 
substantial heterogeneity caused by the measuring 
instrument was found. Therefore, subgroup analysis 
was performed by restricting studies to a similar meas-
uring instrument (PATHFAST, Mitsubishi Chemical 
Medience Corporation, Japan); however, there were 
still heterogeneity in pooled sensitivity and pooled neg-
ative LR (I2 =  91.4  % & I2 =  86.8  %). The forest plots 
implied that the study by Liu et al. has the lowest sen-
sitivity and the highest specificity. After excluding this 
study, heterogeneity still existed in pooled specificity 
(I2 = 53.7 %) and pooled positive LR (I2 = 60.7 %). The 
results in Fig.  4 showed that the study by Endo et  al. 
may account for most of the heterogeneity in pooled 
specificity (I2 = 53.7 %) and pooled positive LR. Statis-
tical pooling of the summary estimates was made after 
Fig. 4 Forest plot of the pooled sensitivity and specificity
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Fig. 5 Forest plot of the pooled positive LR and negative LR
Table 2 Meta-regression analysis for the possible sources of heterogeneity
The RDOR means the DOR for studies that lacked a particular methodologic feature divided by the DOR for studies without the flaw
—, not available, Cte constant term in the equation, RDOR relative diagnostic odds ratio, S indicator of threshold
P < 0.05 indicated the significant relationship between the characteristics of studies and the diagnostic odds ratio
Variances Coefficient standard Standard error P value RDOR 95 % CI
Inverse variance weights 1
 Cte 3.344 0.9147 0.0353 – –
 S 0.228 0.083 0.5130 – –
 Setting 0.341 0.2697 0.2952 1.41 0.60–3.32
 Instrument −0.945 0.4349 0.1180 0.39 0.10–1.55
 Cut-off 0.046 0.0938 0.6558 1.05 0.78–1.41
Inverse variance weights 2
 Cte 3.560 0.8027 0.0114 – –
 S 0.282 0.2884 0.3838 – –
 Setting 0.295 0.2531 0.3082 1.34 0.67–2.71
 Instrument −0.978 0.4297 0.0851 0.38 0.11–1.24
Inverse variance weights 3
 Cte 4.244 0.5481 0.0006 – –
 S 0.458 0.2458 0.1215 – –
 Instrument −1.200 0.3856 0.0265 0.30 0.11–0.81
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outliers excluded and the heterogeneity was eliminated, 
generating the acceptable pooled sensitivity (0.85) and 
pooled specificity (0.65).
The results of our study indicate moderate diagnostic 
performance of presepsin as a single test for diagnosing 
sepsis, which precludes recommendation for the routine 
use of sepsis as a screening or confirmatory test for sep-
sis. We are encouraged about the potential use of pre-
sepsin in combination with other clinical or laboratory 
markers in identifying high-risk patients, although we 
cannot make conclusions about this scenario because 
this was not an objective of the present study. The results 
of the study by Sargentini et  al. confirmed the impor-
tance of monitoring a combination of several biomarkers 
in order to obtain a reliable diagnosis [35].
Because of its retrospective approach, any meta-
analysis is prone to bias; however, we took several steps 
to minimize its impact. First, the selection of studies, 
extraction of data, and assessment of study quality were 
performed by two reviewers independently. Second, our 
study was adhered to the PRISMA statement. Third, only 
the ACCP/SCCM criterion was considered as our ref-
erence standard and studies were excluded if limited to 
restrictive subgroups. What is more, meta-regression 
and subgroup analysis were performed in this systematic 
review and meta-analysis, which made the result of the 
study more stable and reliable.
Fig. 6 The SROC of presepsin for diagnosis sepsis based on meta-regression
Table 3 Meta-regression analysis based on  restricting 
studies to a similar measuring instrument
Pooled results Value 95 % CI P value I2 (%)
Sensitivity 0.75 0.72–0.78 0.0000 91.4
Specificity 0.84 0.79–0.88 0.6635 0.0
Positive LR 4.82 3.69–6.30 0.9627 0.0
Negative LR 0.18 0.09–0.35 0.0000 86.8
Diagnostic OR 18.57 12.98–26.560.2197 32.1
Table 4 Subgroup analysis based on excluding outliers
Pooled results Value 95 % CI P value I2 (%)
Sensitivity 0.85 0.81–0.89 0.1587 37.2
Specificity 0.65 0.59–0.70 0.4438 0.0
Positive LR 2.46 2.03–2.98 0.3472 10.7
Negative LR 0.25 0.19–0.33 0.1079 44.6
Diagnostic OR 9.47 6.38–14.05 0.1013 45.7
Page 11 of 13Zheng et al. Ann. Intensive Care  (2015) 5:48 
Fig. 7 The SROC of presepsin for diagnosis sepsis based on excluding outliers
Fig. 8 Funnel plot of publication bias (P = 0.755)
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In addition, several limitations of this study should be 
put forward. First, studies included in our meta-analysis 
varied substantially in presepsin diagnostic criteria. Sec-
ond, a limited number of studies were included in our 
meta-analysis. Third, the quality of all included studies 
varies substantially and might also influence the results 
of our studies. Therefore, further studies about presep-
sin for diagnostic assessment are need to be investigated, 
both in larger, multi-center studies and in prospective 
clinical studies, with sepsis patients without limited to 
restrictive subgroups.
Conclusion
Our meta-analysis found that the presepsin test has mod-
erate diagnostic ability for the detection of sepsis. On the 
basis of diagnostic accuracy, our data suggest that, before 
widespread clinical use, further research is needed of 
the presepsin test as a diagnostic test used in isolation to 
include or exclude sepsis in emergency department. And 
presepsin in combination with other laboratory biomark-
ers in diagnosing sepsis may be the focus of future studies.
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